Prothena PRTA Stock
Prothena Price Chart
Prothena PRTA Financial and Trading Overview
| Prothena stock price | 6.58 USD |
| Previous Close | 71.85 USD |
| Open | 71.65 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 70.52 - 72.66 USD |
| 52 Week Range | 22.97 - 79.65 USD |
| Volume | 357.79K USD |
| Avg. Volume | 470.42K USD |
| Market Cap | 3.83B USD |
| Beta (5Y Monthly) | 0.360211 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 93 USD |
PRTA Valuation Measures
| Enterprise Value | 3.15B USD |
| Trailing P/E | N/A |
| Forward P/E | -17.786764 |
| PEG Ratio (5 yr expected) | 29.12 |
| Price/Sales (ttm) | 69.70372 |
| Price/Book (mrq) | 6.29347 |
| Enterprise Value/Revenue | 57.299 |
| Enterprise Value/EBITDA | -21.095 |
Trading Information
Prothena Stock Price History
| Beta (5Y Monthly) | 0.360211 |
| 52-Week Change | 204.02% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 79.65 USD |
| 52 Week Low | 22.97 USD |
| 50-Day Moving Average | 64.19 USD |
| 200-Day Moving Average | 55.14 USD |
PRTA Share Statistics
| Avg. Volume (3 month) | 470.42K USD |
| Avg. Daily Volume (10-Days) | 426.38K USD |
| Shares Outstanding | 52.75M |
| Float | 38.68M |
| Short Ratio | 5.68 |
| % Held by Insiders | 4.72% |
| % Held by Institutions | 95.09% |
| Shares Short | 3.32M |
| Short % of Float | 9.25% |
| Short % of Shares Outstanding | 6.29% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -232.19% |
| Operating Margin (ttm) | -273.0069% |
| Gross Margin | -178.68% |
| EBITDA Margin | -271.61% |
Management Effectiveness
| Return on Assets (ttm) | -14.16% |
| Return on Equity (ttm) | -24.37% |
Income Statement
| Revenue (ttm) | 54.92M USD |
| Revenue Per Share (ttm) | 1.13 USD |
| Quarterly Revenue Growth (yoy) | 88.09% |
| Gross Profit (ttm) | -81657000 USD |
| EBITDA | -149175008 USD |
| Net Income Avi to Common (ttm) | -127523000 USD |
| Diluted EPS (ttm) | -2.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 686.18M USD |
| Total Cash Per Share (mrq) | 13.01 USD |
| Total Debt (mrq) | 4.89M USD |
| Total Debt/Equity (mrq) | 0.8 USD |
| Current Ratio (mrq) | 14.327 |
| Book Value Per Share (mrq) | 11.531 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -118864000 USD |
| Levered Free Cash Flow (ttm) | -42870248 USD |
Profile of Prothena
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | 77 Sir John Rogerson’s Quay |
| ZIP | 2 |
| Phone | 353 1 236 2500 |
| Website | https://www.prothena.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 127 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Q&A For Prothena Stock
What is a current PRTA stock price?
Prothena PRTA stock price today per share is 6.58 USD.
How to purchase Prothena stock?
You can buy PRTA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prothena?
The stock symbol or ticker of Prothena is PRTA.
Which industry does the Prothena company belong to?
The Prothena industry is Biotechnology.
How many shares does Prothena have in circulation?
The max supply of Prothena shares is 53.83M.
What is Prothena Price to Earnings Ratio (PE Ratio)?
Prothena PE Ratio is now.
What was Prothena earnings per share over the trailing 12 months (TTM)?
Prothena EPS is -2.05 USD over the trailing 12 months.
Which sector does the Prothena company belong to?
The Prothena sector is Healthcare.
Prothena PRTA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18737.21 USD — |
-1
|
7.88B USD — | 18599.69 USD — | 18841.52 USD — | — - | 7.88B USD — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1331.68 USD — |
<0.01
|
— — | 1319.57 USD — | 1334.78 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2938.23 USD — |
+0.05
|
— — | 2902.53 USD — | 2948.38 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4084.75 USD — |
+0.07
|
— — | 4033.52 USD — | 4091.93 USD — | — - | — — |
| Nasdaq Health Care IXHC | 932.02 USD — |
-0.03
|
— — | 920.46 USD — | 933.54 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4427.65 USD — |
+0.09
|
— — | 4372.13 USD — | 4435.43 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2158.21 USD — |
-0.22
|
— — | 2127.93 USD — | 2163.52 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 9166.82 USD — |
-1.02
|
— — | 9101.76 USD — | 9218.88 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Composite Total Return XCMP | 22955.12 USD — |
-0.99
|
— — | 22786.65 USD — | 23082.91 USD — | — - | — — |
- {{ link.label }} {{link}}